Expert Opinion on Drug Delivery

Expert Opinion on Drug Delivery 由 Taylor and Francis Ltd. 出版，属中科院医学大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 Advanced Drug Delivery Systems、Nanoparticle-Based Drug Delivery、Advancements in Transdermal Drug Delivery 等主题的论文，这 3 个主题约占 39.9%，主导子领域为 Pharmaceutical Science。（根据 OpenAlex 主题统计与中科院分区数据生成）

Aims and scopeJournal metrics Editorial board Expert Opinion on Drug Delivery (1742-5247; 1744-7593) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles in drug delivery. Articles cover all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The journal welcomes: Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders Technology evaluations reviewing a particular drug delivery technology Original research contributions are welcomed in the form of: Delivery technologies, vehicles, formulations and devices; The delivery of specific drugs and therapeutic classes; Modes of entry into the body and applications in certain diseases and disorders. Editorials commenting on the various drug delivery strategies which have been, and are being, explored Guidelines on the application of specific drug delivery systems, or in specific disease indications. Please note that the journal does not publish case reports, case series, or animal studies. The audience for the journal consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Publish in 3 weeks from submission with Accelerated Publication. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Opinion on Drug Delivery, part of the Expert Collecti

摘自期刊官网 Aims & Scope

研究方向（LetPub）：医学-药学

中科院期刊分区表

数据库收录

SCIEScopusLetPub

国际期刊预警名单：各版本均未列入LetPub

期刊官网自述收录

MEDLINE出版商官网

期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

6.06LetPub · 2026-09-13

CiteScore 2026-06

10.7LetPub · 2026-09-13

SJR 2026-06

1.06LetPub · 2026-09-13

SNIP 2026-06

0.98LetPub · 2026-09-13

h-index

88LetPub · 2026-09-13

h-index

161OpenAlex · 2026-10-01

i10-index

1,957OpenAlex · 2026-10-01

两年平均被引

7.02OpenAlex · 2026-10-01

自引率

1.7%LetPub · 2026-09-13

Gold OA 文章占比

5.71%LetPub · 2026-09-13

发文规模

年文章数

131LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

平均审稿速度（社区反馈）

偏慢,4-8周LetPub · 2026-09-13

评审方式

双盲同行评审出版商官网

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Taylor and Francis Ltd.

出版国家或地区

ENGLAND

出版语言

English

出版周期

Bimonthly

创刊年份

2004

ISSN

1742-5247

电子版 ISSN

1744-7593

官网最新一期

Volume 23, Issue 9（2026 年）

官方链接

• 期刊主页 ↗OpenAlex
• 投稿系统 ↗出版商官网
• 专刊 / 特刊征稿 ↗出版商官网